This information is for educational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional.
HealthdirectFree Australian health advice you can count on. — Description, Dosage, Side Effects | PillsCard
OTC
HealthdirectFree Australian health advice you can count on.
INN: avelumab
Data updated: 2026-04-25
Available in:
🇨🇿🇬🇧🇫🇷🇵🇹🇷🇺🇸🇰
Form
—
Dosage
—
Route
—
Storage
—
About This Product
User Reviews
Reviews reflect personal experiences and are not medical advice. Always consult your doctor.
Manufacturer
Merck Europe B.V.
ATC Code
L01FF04
Source
EMA · EMEA/H/C/004338
(
ARTG
)
BAVENCIO is indicated for the treatment of adults and paediatric patients 12 years and older
with metastatic Merkel cell carcinoma (mMCC). This indication is approved based on tumour
response rate, duration of response in a single arm study.,BAVENCIO is indicated for the first-line maintenance treatment of patients with locally
advanced or metastatic urothelial carcinoma (UC) whose disease has not progressed with
first-line platinum-based induction chemotherapy.,BAVENCIO in combination with axitinib is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC).
⚠️ Warnings
•Patients should be monitored very closely for the following serious adverse reactions and the therapy should either be withheld or permanently discontinued based on the patient’s condition:
•
•
Pneumonitis
• Hepatitis
• Colitis
• Endocrinopathies such as thyroid disorders, adrenal insufficiency, and type 1 diabetes mellitus
• Infusion-related infections such as fever, low blood pressure or difficulty in breathing